• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis".

作者信息

Ismaila Afisi S, Haeussler Katrin, Malmenäs Mia, Sharma Raj, Compton Chris, Vogelmeier Claus F, Han MeiLan K, Halpin David M G

机构信息

Value Evidence and Outcomes, GSK, 1250 South Collegeville Road, Collegeville, PA, 19426-0989, USA.

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.

出版信息

Adv Ther. 2023 May;40(5):2556-2561. doi: 10.1007/s12325-023-02495-0. Epub 2023 Apr 1.

DOI:10.1007/s12325-023-02495-0
PMID:37004642
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10129919/
Abstract
摘要

相似文献

1
A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis".对《致编辑的信：关于“糠酸氟替卡松/乌美溴铵/维兰特罗（FF/UMEC/VI）三联疗法与其他疗法治疗慢性阻塞性肺疾病的网络荟萃分析”》的回应
Adv Ther. 2023 May;40(5):2556-2561. doi: 10.1007/s12325-023-02495-0. Epub 2023 Apr 1.
2
Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis".致编辑的信：关于“糠酸氟替卡松/乌美溴铵/维兰特罗（FF/UMEC/VI）三联疗法与其他疗法治疗慢性阻塞性肺疾病的网络荟萃分析”
Adv Ther. 2023 May;40(5):2549-2555. doi: 10.1007/s12325-023-02491-4. Epub 2023 Apr 1.
3
Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.糠酸氟替卡松/乌美溴铵/维兰特罗（FF/UMEC/VI）三联疗法与其他 COPD 治疗药物的比较：一项网状荟萃分析。
Adv Ther. 2022 Sep;39(9):3957-3978. doi: 10.1007/s12325-022-02231-0. Epub 2022 Jul 17.
4
Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes.糠酸氟替卡松/乌美溴铵/维兰特罗起始治疗 COPD 加重：早期起始治疗对 COPD 结局的获益。
Adv Ther. 2024 Dec;41(12):4557-4580. doi: 10.1007/s12325-024-02999-3. Epub 2024 Oct 25.
5
Cost-effectiveness analysis of fluticasone furoate/umeclidinium bromide/vilanterol and umeclidinium bromide/vilanterol in the management of moderate and severe COPD in China.氟替卡松/乌美溴铵/维兰特罗与乌美溴铵/维兰特罗在中国中重度 COPD 管理中的成本效果分析。
Respir Med. 2024 May;226:107632. doi: 10.1016/j.rmed.2024.107632. Epub 2024 Apr 16.
6
Bayesian or frequentist: there is no question when comparing single-inhaler triple therapies via network meta-analysis. Focus on fluticasone furoate/umeclidinium/vilanterol fixed-dose combination in chronic obstructive pulmonary disease.贝叶斯或频率派：通过网络荟萃分析比较单吸入器三联疗法时，无需质疑。重点关注糠酸氟替卡松/乌美溴铵/维兰特罗固定剂量复方制剂在慢性阻塞性肺疾病中的应用。
Expert Rev Respir Med. 2023 Dec;17(12):1273-1283. doi: 10.1080/17476348.2024.2316167. Epub 2024 Feb 16.
7
Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease.糠酸氟替卡松/乌美溴铵/维兰特罗与布地奈德/格隆溴铵/富马酸福莫特罗在美国慢性阻塞性肺疾病患者中的疗效比较
Adv Ther. 2025 Feb;42(2):1131-1146. doi: 10.1007/s12325-024-03088-1. Epub 2024 Dec 28.
8
A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD.糠酸氟替卡松/维兰特罗联合用药治疗稳定期慢性阻塞性肺疾病的系统评价及荟萃分析
Pulm Pharmacol Ther. 2017 Feb;42:1-6. doi: 10.1016/j.pupt.2016.11.003. Epub 2016 Nov 15.
9
Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病患者中糠酸氟替卡松/乌美溴铵/维兰特罗的群体药代动力学分析。
Clin Pharmacokinet. 2020 Jan;59(1):67-79. doi: 10.1007/s40262-019-00794-w.
10
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.血液嗜酸性粒细胞与慢性阻塞性肺疾病三联和双联治疗反应：IMPACT 试验分析。
Lancet Respir Med. 2019 Sep;7(9):745-756. doi: 10.1016/S2213-2600(19)30190-0. Epub 2019 Jul 4.

本文引用的文献

1
Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score.比较慢性阻塞性肺疾病三联固定剂量组合的疗效和安全性：一项荟萃分析和IBiS评分
J Clin Med. 2022 Aug 1;11(15):4491. doi: 10.3390/jcm11154491.
2
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.乌美溴铵/维兰特罗与其他支气管扩张剂治疗慢性阻塞性肺疾病的疗效比较：一项网络荟萃分析。
Adv Ther. 2022 Nov;39(11):4961-5010. doi: 10.1007/s12325-022-02234-x. Epub 2022 Jul 20.
3
Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.糠酸氟替卡松/乌美溴铵/维兰特罗（FF/UMEC/VI）三联疗法与其他 COPD 治疗药物的比较：一项网状荟萃分析。
Adv Ther. 2022 Sep;39(9):3957-3978. doi: 10.1007/s12325-022-02231-0. Epub 2022 Jul 17.
4
Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety.比较 COPD 初始 LABA-ICS 吸入器：真实世界的疗效和安全性。
Respir Med. 2021 Nov-Dec;189:106645. doi: 10.1016/j.rmed.2021.106645. Epub 2021 Oct 7.
5
Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis.三种（吸入皮质激素/长效毒蕈碱拮抗剂/长效β-激动剂）疗法治疗慢性阻塞性肺疾病的疗效和安全性比较：系统评价和贝叶斯网络荟萃分析。
Respiration. 2021;100(7):631-643. doi: 10.1159/000515133. Epub 2021 May 10.
6
Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.布地奈德/格隆溴铵/富马酸福莫特罗与其他三联复方制剂治疗 COPD 的疗效和安全性：系统文献评价和网络荟萃分析。
Adv Ther. 2021 Jun;38(6):3089-3112. doi: 10.1007/s12325-021-01703-z. Epub 2021 Apr 30.
7
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.在 COPD 患者中，每日一次单吸入器与每日两次多吸入器三联疗法的比较：来自两项复制随机对照试验的肺功能和健康状况结果。
Respir Res. 2020 May 29;21(1):131. doi: 10.1186/s12931-020-01360-w.
8
Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.布地奈德/格隆溴铵/富马酸福莫特罗干粉吸入剂（BGF MDI）对比其他吸入性皮质类固醇/长效毒蕈碱拮抗剂/长效β激动剂（ICS/LAMA/LABA）三联复方制剂治疗 COPD 的疗效：系统文献评价和网络荟萃分析。
Adv Ther. 2020 Jun;37(6):2956-2975. doi: 10.1007/s12325-020-01311-3. Epub 2020 Apr 25.
9
Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis.茚达特罗格隆溴铵与噻托溴铵/奥达特罗治疗初治中度症状性慢性阻塞性肺疾病患者的事后分析
Pulm Ther. 2018 Dec;4(2):171-183. doi: 10.1007/s41030-018-0057-7. Epub 2018 Jun 20.
10
A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.一项关于甘罗溴铵/富马酸福莫特罗定量吸入气雾剂相对于乌美溴铵/维兰特罗干粉吸入剂治疗 COPD 的随机、双盲、双模拟研究。
Adv Ther. 2019 Sep;36(9):2434-2449. doi: 10.1007/s12325-019-01015-3. Epub 2019 Jul 2.